Synapsoft logo
AI Insights from Disclosures
Searching...
ImmuneOncia Therapeutics, Inc. 424870
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
ImmuneOncia Therapeutics, Inc. is a company specializing in the development of antibody-based cancer immunotherapies. The company holds Anti-PD-L1, Anti-CD47, and Anti-LAG-3 monoclonal antibodies as its core assets, and its basic business model is to develop new drug candidates based on these antibodies and generate revenue through out-licensing at an early clinical stage.
Representative Director Kim Heungtae
Founded September 1, 2016
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 13451-0299881
Business number 404-87-00519
Phone Number 02-6283-5096
Fax Number 0316229014
Company Address 25 Tapsil-ro 35beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant